Search Results - "Mentenich, Nicole"

Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study by Ruilope, Luis M, Pitt, Bertram, Anker, Stefan D, Rossing, Peter, Kovesdy, Csaba P, Pecoits-Filho, Roberto, Pergola, Pablo, Joseph, Amer, Lage, Andrea, Mentenich, Nicole, Scheerer, Markus F, Bakris, George L

“…In FIGARO-DKD, finerenone reduced the risk of cardiovascular events in patients with type 2 diabetes (T2D) and stage 1-4 chronic kidney disease (CKD). In…”
Get full text

Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes by Ruilope, Luis M., Agarwal, Rajiv, Anker, Stefan D., Filippatos, Gerasimos, Pitt, Bertram, Rossing, Peter, Sarafidis, Pantelis, Schmieder, Roland E., Joseph, Amer, Mentenich, Nicole, Nowack, Christina, Bakris, George L.

Get full text

Finerenone and Kidney Outcomes in Patients with CKD and Type 2 Diabetes: Results from FIGARO-DKD: SA-OR21 by Bakris, George L., Ruilope, Luis M., Rossing, Peter, Anker, Stefan D., Pitt, Bertram, Filippatos, Gerasimos, Mentenich, Nicole, Lage, Andrea Z., Scheerer, Markus, Joseph, Amer, Agarwal, Rajiv

Get full text

FC 090EFFECTS OF FINERENONE ON CARDIORENAL OUTCOMES IN BLOOD PRESSURE SUBGROUPS IN PATIENTS WITH CKD AND T2D by Ruilope, Luis, Agarwal, Rajiv, Anker, Stefan D, Filippatos, Gerasimos, Pitt, Bertram, Rossing, Peter, Sarafidis, Pantelis, Schmieder, Roland E, Joseph, Amer, Mentenich, Nicole, Nowack, Christina, Bakris, George

“…Abstract Background and Aims Finerenone is a novel, selective, nonsteroidal mineralocorticoid receptor antagonist (MRA) that significantly reduced the risk of…”
Get full text